Literature DB >> 20001993

Family analysis of immunoglobulin classes and subclasses in children with autistic disorder.

Mirko Spiroski1, Vladimir Trajkovski, Dejan Trajkov, Aleksandar Petlichkovski, Olivija Efinska-Mladenovska, Slavica Hristomanova, Eli Djulejic, Meri Paneva, Jadranka Bozhikov.   

Abstract

Autistic disorder is a severe neurodevelopment disorder characterized by a triad of impairments in reciprocal social interaction, verbal and nonverbal communication, and a pattern of repetitive stereotyped activities, behaviours and interests. There are strong lines of evidence to suggest that the immune system plays an important role in the pathogenesis of autistic disorder. The aim of this study was to analyze quantitative plasma concentration of immunoglobulin classes, and subclasses in autistic patients and their families. The investigation was performed retrospectively in 50 persons with autistic disorder in the Republic of Macedonia. Infantile autistic disorder was diagnosed by DSM-IV and ICD-10 criteria. Plasma immunoglobulin classes (IgM, IgA, and IgG) and subclasses (IgG1, IgG2, IgG3, and IgG4) were determined using Nephelometer Analyzer BN-100. Multiple comparisons for the IgA variable have shown statistically significant differences between three pairs: male autistic from the fathers (p = 0,001), female autistic from the mothers (p = 0,008), as well as healthy sisters from the fathers (p = 0,011). Statistically significant differences found between three groups regarding autistic disorder (person with autistic disorder, father/mother of a person with autistic disorder, and brother/sister) independent of sex belongs to IgA, IgG2, and IgG3 variables. Multiple comparisons for the IgA variable have shown statistically significant differences between children with autistic disorder from the fathers and mothers (p < 0,001), and healthy brothers and sisters from the fathers and mothers (p < 0,001). Comparison between healthy children and children with autistic disorder from the same family should be tested for immunoglobulin classes and subclasses in order to avoid differences between generations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20001993      PMCID: PMC5603683          DOI: 10.17305/bjbms.2009.2789

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  25 in total

1.  Peripheral lymphocyte subsets and other immune aspects in Rett syndrome.

Authors:  A Fiumara; A Sciotto; R Barone; G D'Asero; S Munda; E Parano; L Pavone
Journal:  Pediatr Neurol       Date:  1999-09       Impact factor: 3.372

2.  Immunological treatments for autism.

Authors:  S Gupta
Journal:  J Autism Dev Disord       Date:  2000-10

3.  Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders.

Authors:  A M Connolly; M G Chez; A Pestronk; S T Arnold; S Mehta; R K Deuel
Journal:  J Pediatr       Date:  1999-05       Impact factor: 4.406

4.  Circulating autoantibodies to neuronal and glial filament proteins in autism.

Authors:  V K Singh; R Warren; R Averett; M Ghaziuddin
Journal:  Pediatr Neurol       Date:  1997-07       Impact factor: 3.372

Review 5.  Immunogenetic studies in autism and related disorders.

Authors:  R P Warren; V K Singh; R E Averett; J D Odell; A Maciulis; R A Burger; W W Daniels; W L Warren
Journal:  Mol Chem Neuropathol       Date:  1996 May-Aug

6.  Antibrain antibodies in children with autism and their unaffected siblings.

Authors:  Harvey S Singer; Christina M Morris; Phillip N Williams; Dustin Y Yoon; John J Hong; Andrew W Zimmerman
Journal:  J Neuroimmunol       Date:  2006-07-13       Impact factor: 3.478

7.  Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A.

Authors:  A Vojdani; A W Campbell; E Anyanwu; A Kashanian; K Bock; E Vojdani
Journal:  J Neuroimmunol       Date:  2002-08       Impact factor: 3.478

8.  Antibodies to myelin basic protein in children with autistic behavior.

Authors:  V K Singh; R P Warren; J D Odell; W L Warren; P Cole
Journal:  Brain Behav Immun       Date:  1993-03       Impact factor: 7.217

9.  Cortical serotonin type-2 receptor density in parents of children with autism spectrum disorders.

Authors:  Jeremy Goldberg; George M Anderson; Lonnie Zwaigenbaum; Geoffrey B C Hall; Claude Nahmias; Ann Thompson; Peter Szatmari
Journal:  J Autism Dev Disord       Date:  2008-07-01

10.  Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism.

Authors:  A Vojdani; J B Pangborn; E Vojdani; E L Cooper
Journal:  Int J Immunopathol Pharmacol       Date:  2003 Sep-Dec       Impact factor: 3.219

View more
  5 in total

Review 1.  Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?

Authors:  Dominika Gładysz; Amanda Krzywdzińska; Kamil K Hozyasz
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

2.  Low serum IgA and increased expression of CD23 on B lymphocytes in peripheral blood in children with regressive autism aged 3-6 years old.

Authors:  Jolanta Wasilewska; Maciej Kaczmarski; Anna Stasiak-Barmuta; Jolanta Tobolczyk; Ewa Kowalewska
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

Review 3.  A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder.

Authors:  Daniel A Rossignol; Richard E Frye
Journal:  J Pers Med       Date:  2021-05-30

Review 4.  Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes.

Authors:  Richard E Frye; Daniel A Rossignol
Journal:  Clin Med Insights Pediatr       Date:  2016-06-15

Review 5.  Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?

Authors:  Maria de Los Angeles Robinson-Agramonte; Elena Noris García; Jarasca Fraga Guerra; Yamilé Vega Hurtado; Nicola Antonucci; Neomar Semprún-Hernández; Stephen Schultz; Dario Siniscalco
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.